Phase II Study of Ifosfamide, Etoposide and Cisplatin(IEP) Chemotherapy for Advanced Non-Small Cell Lung Cancer

To evaluste the efficacy and toxicity of IEP chemotherapy in locally advanced and metastatic non-small cell lung cancer, nineteen previously untreated patients with non-small cell lung cancer were studied.

Patients received ifosfamide 1000mg/m² with mesna, 20% of ifosfamide dose at 0,4, 8 hours after ifosfamide, etoposide 100mg/m², and cisplatin 20mg/m² with full hydration and mannitol diuresis intravenously on days 1-3 every 4 weeks.

Eighteen male and one female, two stage IIIA, 10 stage IIIB and 7 stage IV patients have been treated.

The response rate of IEP was 26% with no complete remission, 53% of stable disease, and 23% of progressive diasease.

The overall median survival was not reaced yet and 20 month survival rate was 51.4%, The duration of remission was at the range of 4⁺ to 40 weeks.

The toxicities were alopecia(100%), nausea and vomiting(47%), leukopenia(14%), infection(6%), renal dysfunction(6%) and oral mucositis(5%).

This phase II study of IEP in advanced non-small cell lung cancer is not superior to another combination regimens in terms of response but toxicity was tolerable. Other new chemotherapeutic drugs and newer trials should be developed further.